Akebia Therapeutics, Inc. (AKBA)
NASDAQ: AKBA · Real-Time Price · USD
0.6955
-0.0065 (-0.93%)
At close: Oct 15, 2026, 4:00 PM EDT
0.722326
+0.0268 (3.86%)
After-hours: Oct 15, 2026, 7:59 PM EDT
Akebia Therapeutics Employees
Akebia Therapeutics had 194 employees as of December 31, 2025. The number of employees increased by 13 or 7.18% compared to the previous year. That makes Akebia Therapeutics the 27,027th largest employer in the world and 3,426th in the United States.
Employees
194
Change (1Y)
13
Growth (1Y)
7.18%
Revenue / Employee
$1,129,175
Profits / Employee
-$152,918
Market Cap
192.73M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 194 | 13 | 7.18% | 194 | 0 |
| Dec 31, 2024 | 181 | 14 | 8.38% | 181 | 0 |
| Dec 31, 2023 | 167 | -38 | -18.54% | 167 | 0 |
| Dec 31, 2022 | 205 | -221 | -51.88% | 204 | 1 |
| Dec 31, 2021 | 426 | 46 | 12.11% | 426 | 0 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Canopy Growth | 1,128 |
| Aurora Cannabis | 1,028 |
| Organogenesis Holdings | 854 |
| Lifecore Biomedical | 382 |
| Anika Therapeutics | 235 |
| ADC Therapeutics | 193 |
| BioAge Labs | 62 |
| Journey Medical | 58 |
AKBA News
- 8 days ago - Akebia Therapeutics to Conduct Investor Meetings at the Virtual U.S. Bancorp I BTIG Kidney Health Forum - GlobeNewsWire
- 9 days ago - Akebia Therapeutics Announces Late-Breaking VOICE Trial Presentation and Posters on Akebia's Rare Kidney Pipeline at ASN Kidney Week 2026 - GlobeNewsWire
- 14 days ago - Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 23 days ago - Scynexis appoints Burke to Board of Directors - TheFly
- 4 weeks ago - Akebia doses first patient in ebribafusp trial - TheFly
- 4 weeks ago - Akebia Therapeutics Announces First Patient Dosed in Phase 2 Basket Trial of Ebribafusp in Rare Complement-Mediated Kidney Diseases - GlobeNewsWire
- 5 weeks ago - Akebia initiated with a Buy at WestPark Capital - TheFly
- 6 weeks ago - Akebia Therapeutics to Conduct Investor Meetings at the 2026 Wells Fargo Healthcare Conference in Boston - GlobeNewsWire